摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    0.8
  • 重原子数:
    22
  • 可旋转键数:
    0
  • 环数:
    5.0
  • sp3杂化的碳原子比例:
    0.53
  • 拓扑面积:
    55.8
  • 氢给体数:
    0
  • 氢受体数:
    4

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

点击查看最新优质反应信息

文献信息

  • Synthetic Studies on Cephalotaxus Alkaloids. A synthesis of (.+-.)-Cephalotaxine.
    作者:Masazumi IKEDA、Masahiko OKANO、Keigo KOSAKA、Masaru KIDO、Hiroyuki ISHIBASHI
    DOI:10.1248/cpb.41.276
    日期:——
    A stereoselective total synthesis of (±)-cephalotaxine (1) has been achieved. Palladium-catalyzed [3+2] cycloaddition of 2-(trimethylsilylmethyl)-2-propenyl acetate to the nitrostyrene 7 gave the methylenecyclopentane 6, which was converted into the α-sulfinylacetamide 19. Treatment of 19 either with trifluoroacetic anhydride in dichloromethane at room temperature or with p-toluenesulfonic acid in boiling 1, 2-dichloroethane gave the benzazepinone 20 in good yield, and this was transformed to (±)-1 via Hanaoka's key intermediate 4.
    已实现(±)-cephalotaxine (1)的立体选择性全合成。利用钯催化的[3+2]环加成反应,将2-(三甲基硅烷基甲基)-2-丙烯基乙酸酯与硝基乙烯7反应,得到亚甲基环戊烷6,其随后转化为α-亚砜乙酰胺19。在室温下,将19与二氯甲烷中的三氟乙酸酐或与沸腾的1,2-二氯乙烷中的对甲苯磺酸反应,均能以良好产率获得苯并氮杂卓酮20,并通过Hanaoka的关键中间体4将其转化为(±)-1。
  • Total synthesis of (±)-cephalotaxine
    作者:Hiroyuki Ishibashi、Masahiko Okano、Hiroshi Tamaki、Kazumi Maruyama、Takayuki Yakura、Masazumi Ikeda
    DOI:10.1039/c39900001436
    日期:——
    A total synthesis of (±)-cephalotaxine has been achieved in a stereoselective manner by a synthetic sequence involving an acid-catalysed cyclisation of the α-sulphinylacetamide 12 as a key step.
    (±)-头孢他辛的全合成已经通过立体选择的方式实现,该合成顺序涉及一个关键步骤,该合成序列涉及酸催化的α-亚磺酰基乙酰胺12的环化。
  • A Formal Total Synthesis of (-)-Cephalotaxine.
    作者:Masaszumi IKEDA、Serry A.A. EL BIALY、Ken-ichi HIROSE、Miho KOTAKE、Tatsunori SATO、Said M.M. BAYOMI、Ihsan A. SHEHATA、Ali M. ABDELAL、Laila M. GAD、Takayuki YAKURA
    DOI:10.1248/cpb.47.983
    日期:——
    A formal total synthesis of (-)-cephalotaxine (1) has been achieved. The key step is an intramolecular aldol condensation of the diketone 9, which in turn was obtained in three steps from the azabicyclic compound 6 derived from D-proline according to Seebach's procedure. Treatment of 9 with a catalytic amount of sodium 2-methyl-2-butanolate in benzene at room temperature gave the alpha, beta-unsaturated
    (-)-头孢他辛(1)的正式合成已经完成。关键步骤是二酮9的分子内醇醛缩合,其又按照Seebach的方法从衍生自D-脯氨酸的氮杂双环化合物6中分三步得到。在室温下用催化量的2-甲基-2-丁醇钠的苯催化处理9,得到α,β-不饱和酮8,产率为43%。催化氢化8,然后用硼氢化钠还原酮22,并将所得醇23乙酰化,得到乙酰氧基衍生物24,在脱保护后,用(甲硫基)乙酸酰化得到酰胺26。将化合物26转化继开发用于合成外消旋化合物的合成操作后,生成旋光的酮内酰胺4。
  • Enantioselective Divergent Syntheses of <i>Cephalotaxus</i> Alkaloids: (−)-Cephalotaxine, (−)-Cephalotine B, and (−)-Fortuneicyclidins A and B
    作者:Xian-Tao An、Xiao-Min Ge、Xin-Yu Liu、Yu-Han Yang、Xian-He Zhao、Xiao-Yan Ma、Chao Peng、Yi-Jun Fan、Yong Qin、Chun-An Fan
    DOI:10.1021/jacs.3c01572
    日期:2023.4.26
    block with the tetracyclic A/B/C/D ring system, a concise enantioselective total synthesis of (−)-cephalotaxine starting from readily available homopiperonyl alcohol has been achieved in nine steps with only two column chromatography purifications. Following the tactical introduction of the Meinwald rearrangement, enantioselective divergent syntheses of (−)-cephalotine B with an additional C3–O–C11
    开发了一种新策略,重点关注环 D 的最后阶段不对称组装,它固有地拥有 (−)-头孢紫杉醇 A/B/C/D 环系统中最密集的手性中心和官能团部分,其中设计并探索了一种新型 Rh 催化的叔烯酰胺与烯醇重氮乙酸酯的不对称 (2 + 3) 环化反应,用于对映选择性构建具有独特螺环氮杂-季立构中心的关键环戊烷环 D。基于使用四环 A/B/C/D 环系统快速获得手性功能化结构单元,以现成的高胡椒醇为起始原料,仅用两根色谱柱,通过九个步骤实现了 (−)-头孢紫杉醇的简明对映选择性全合成层析纯化。
  • El Bialy, Serry A. A.; Ismail, Mohamed A.; Gad, Lila M., Medicinal Chemistry Research, 2002, vol. 11, # 5, p. 293 - 300
    作者:El Bialy, Serry A. A.、Ismail, Mohamed A.、Gad, Lila M.、Abdelal, Ali M. M.
    DOI:——
    日期:——
查看更多

同类化合物

高三尖杉酯碱酰胺 高三尖杉酯碱 氧桥三尖杉碱 异三尖杉酯碱 双(去甲基)-脱氧三尖杉酯碱 去甲基三尖杉酮碱 去氧哈林通碱 乙酰三尖杉碱 三尖杉酯碱 三尖杉碱 4-羟基三尖杉碱 4'-去甲基高三尖杉酯碱 (1S,3aR)-1,5,6,8,9,14bbeta-六氢-2-甲氧基-4H-环戊并[a][1,3]二氧杂环戊并[4,5-H]吡咯并[2,1-b][3]苯并氮杂卓-1alpha,9alpha-二醇 (-)-脱水三尖杉酯碱 nordeoxyharringtonine cephalotaxine 4′-demethylharringtonine homoharringtonine α-N-oxide cephalotaxine α-N-oxide cephalotaxine α-N-oxide cephalotaxine β-N-oxide (2R,3R,4S,5S)-2,3-bis(tert-butyldiphenylsilyloxy)-cephalotaxan-8-one (2S,3R,5S,7S)-3-methyl-4,17,19-trioxa-11-azahexacyclo[12.7.0.02,7.03,5.07,11.016,20]henicosa-1(21),14,16(20)-triene (2S,6S)-3-methyl-16,18-dioxa-10-azapentacyclo[11.7.0.02,6.06,10.015,19]icosa-1(20),3,13,15(19)-tetraene (1S)-2-methoxy-(3atC4,14bt)-1,5,6,8,9,14b-hexahydro-4H-1r,9c-epioxido-cyclopenta[b][1,3]dioxolo[4',5':4,5]benzo[1,2-d]pyrrolo[1,2-a]azepine 1-O-[(2R,3S,6R)-4-methoxy-16,18-dioxa-10-azapentacyclo[11.7.0.02,6.06,10.015,19]icosa-1(20),4,13,15(19)-tetraen-3-yl] 4-O-methyl 2-hydroxy-2-(4-hydroxy-4-methylpentyl)butanedioate 2,3,5,6,8,9-hexahydro-1-(pivaloyloxy)-4H-cyclopenta<1,3>dioxolo<4,5-h>pyrrolo<2,1-b><3>benzazepine Dimethyl 3-(trifluoromethylsulfonyloxy)-16,18-dioxa-10-azapentacyclo[11.7.0.02,6.06,10.015,19]icosa-1(20),2,7,13,15(19)-pentaene-7,8-dicarboxylate Alkaloid D Epicephalotaxin Cephalotaxin a u. b (3aα,4aS*,15bβ,15cα)-(+/-)-3a,4,6,7,9,10,15b,15c-octahydro-2,2-dimethyl-5H-<1,3>dioxolo<4,5-h>-1,3-dioxolo<4,5>cyclopenta<1,2-a>pyrrolo<2,1-b><3>-benzazepine 4-Hydroxy-16,18-dioxa-10-azapentacyclo[11.7.0.02,6.06,10.015,19]icosa-1(20),13,15(19)-trien-3-one (Ξ)-2-methyl-2-(2,2,2-trichloro-ethoxycarbonyloxy)-butyric acid (3aR)-2-methoxy-(3arC4,14bc)-1,5,6,8,9,14b-hexahydro-4H-cyclopenta[b][1,3]dioxolo[4',5':4,5]benzo[1,2-d]pyrrolo[1,2-a]azepin-1t-yl ester (3aR)-2-methoxy-1t-(2,2,2-trichloro-ethoxycarbonyloxy)-(3arC4,14bc)-1,5,6,8,9,14b-hexahydro-4H-cyclopenta[b][1,3]dioxolo[4',5':4,5]benzo[1,2-d]pyrrolo[1,2-a]azepine (S)-phenyl-(2,2,2-trichloro-ethoxycarbonyloxy)-acetic acid (3aR)-2-methoxy-(3arC4,14bc)-1,5,6,8,9,14b-hexahydro-4H-cyclopenta[b][1,3]dioxolo[4',5':4,5]benzo[1,2-d]pyrrolo[1,2-a]azepin-1t-yl ester oxalic acid ethyl ester (3aR)-2-methoxy-(3arC4,14bc)-1,5,6,8,9,14b-hexahydro-4H-cyclopenta[b][1,3]dioxolo[4',5':4,5]benzo[1,2-d]pyrrolo[1,2-a]azepin-1t-yl ester (3aR)-1t-benzyloxycarbonyloxy-2-methoxy-(3arC4,14bc)-1,5,6,8,9,14b-hexahydro-4H-cyclopenta[b][1,3]dioxolo[4',5':4,5]benzo[1,2-d]pyrrolo[1,2-a]azepine (S)-hydroxy-phenyl-acetic acid (3aR)-2-methoxy-(3arC4,14bc)-1,5,6,8,9,14b-hexahydro-4H-cyclopenta[b][1,3]dioxolo[4',5':4,5]benzo[1,2-d]pyrrolo[1,2-a]azepin-1t-yl ester [(2S,3S,6R)-4-methoxy-16,18-dioxa-10-azapentacyclo[11.7.0.02,6.06,10.015,19]icosa-1(20),4,13,15(19)-tetraen-3-yl] (2R)-2-[2-(furan-2-ylmethylamino)-2-oxoethyl]-2,6-dihydroxy-6-methylheptanoate (+/-)-3-dehydroxy-2-demethoxy-1,2-dihydro-2,8-dioxocephalotaxine epi-deoxyharringtonine hexa-2t,4t-dienoic acid (3aR)-2-methoxy-(3arC4,14bc)-1,5,6,8,9,14b-hexahydro-4H-cyclopenta[b][1,3]dioxolo[4',5':4,5]benzo[1,2-d]pyrrolo[1,2-a]azepin-1t-yl ester Dehydrodeoxyhomoharringtonine [(2S,4S,6S)-12-methylsulfanyl-11-oxo-16,18-dioxa-10-azapentacyclo[11.7.0.02,6.06,10.015,19]icosa-1(20),13,15(19)-trien-4-yl] acetate Omacetaxine mepesuccinate hydrochloride cephalotaxinamide (1R,2S,3aS,14bR)-1,2,3,5,6,8,9,14b-Octahydro-4H-cyclopenta<1,3>dioxolo<4,5-h>pyrrolo<2,1-b><3>benzazepine-1,2-diol methylfumaric acid 1-((3aR)-2-methoxy-(3arC4,14bc)-1,5,6,8,9,14b-hexahydro-4H-cyclopenta[b][1,3]dioxolo[4',5':4,5]benzo[1,2-d]pyrrolo[1,2-a]azepin-1t-yl) ester 4-methyl ester 11alpha-Hydroxycephalotaxine